Dr. Marc Poirot is first class research director at the Institut National de la Santé et de la Recherche Médicale (INSERM). He heads the team ‘Sterol metabolism and therapeutic innovations in oncology’ University of Toulouse, France. He received a PhD in Chemical Biology from the University of Toulouse. He did a post-doc at Sanofi in 1991 before becoming tenured at INSERM. He was visiting scientist from 1993 to 1996 in the laboratory of Dr Stoney S. Simons Jr (NIDDK/NIH, Bethesda, USA). He is co-author of 65 publications and 15 patents.
Dr. Marc Poirot’s research area is focused on the elucidation the mechanisms of action of the anti-tumor drug tamoxifen, which led to the definition of the importance of the microsomal anti-estrogen binding site (AEBS) and of oxysterol metabolism in its pharmacology. His main research interests are the study of deregulations in sterol metabolic pathways in cancers and other degenerative diseases, the identification and the characterization of new sterol metabolites involved in these physiopathologic deregulations.
